Condition: Advanced MDS · AML · Sponsor: Immune System Key Ltd
This is an open-label Phase 1b study of NEROFE following a traditional 3+3 design to assess safety and to determine the Recommended Phase 2 Dose (RP2D) of NEROFE in patients with MDS or AML. IV NEROFE will be administered three times per week on alternate days. The exact dosage will be determined using the body surface area (BSA) measured on Day 1 of each cycle.
This description comes directly from the study's public registry record.
Justin Watts, MD · 305-243-3084 · jxw401@miami.edu
Amber Thomassen, APRN-BC · 305-243-7042 · axt283@miami.edu
Always discuss trial participation with your own doctor first.
| University of Miami Hospital and Clinics / Sylvester Comprehensive Cancer Center | Miami, Florida, United States | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT04365179